Small Dallas study explores radiation before kidney cancer surgery

A small Dallas clinical trial has examined whether targeted radiation before surgery could help patients whose kidney cancer extends into major veins. The findings, published October 15 in JAMA Oncology, offer a basis for further research rather than proof that the approach outperforms existing care.

The UT Southwestern study recruited participants through the university and Parkland Health. Twenty-three patients received radiation, 22 completed surgery, and 21 were included in the primary recurrence-free survival analysis.

That analysis estimated one-year recurrence-free survival at 71.4%, compared with a historical benchmark of 55.7%. The study did not randomly assign patients to a comparison group. Its small size and comparison with patients treated at a different time limit what can be concluded about the difference.

The researchers reported four grade-3, or severe, adverse events attributed to radiation, underscoring that the treatment carried risks. The paper also cautioned that observations of tumors shrinking outside the treated area were anecdotal and did not establish an immune-system effect.

The results do not show that radiation before surgery should become standard treatment. Larger comparative studies are needed to test whether the approach improves outcomes.